Leerink Partners Raises Price Target on UnitedHealth Group (UNH) to $195; Reiterates Outperform

UBS Raises Price Target on UnitedHealth Group (UNH) Following Investor Day

UBS reiterated a Buy rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $193.00 (from $180.00), following the company's investor day. UNH expects its Medicare Advantage enrollment to grow by 700-800K lives in 2017, a 19-22% Y/Y increase. UBS raised 2016 EPS estimates to $9.45 and... More

UnitedHealth Group (UNH) PT Raised to $171 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn reiterated an Outperform rating and raised his price target on UnitedHealth Group (NYSE: UNH) to $171.00 (from $161.00) following its analyst day.

Wiederhorn commented, "UnitedHealth Group issued FY2017 adj. EPS guidance of $9.30-9.60, well ahead of OPCO/Street estimates of... More

UnitedHealth Group (UNH) PT Raised to $182 at Jefferies

Jefferies analyst David Windley reiterated a Buy and raised his price target on UnitedHealth Group (NYSE: UNH) to $182.00 (from $168.00) following the company's analyst day yesterday.

Windley commented, "In case you didn't hear, UNH had a small get together Tuesday in NY highlighting... More

Mizuho Securities Upgrades UnitedHealth Group (UNH) to Buy

Mizuho Securities upgraded UnitedHealth Group (NYSE: UNH) from Neutral to Buy with a price target of $178.00.

Analyst Sheryl Skolnick commented, "Despite the still-uncertain politics of health care, we are raising our rating on UNH shares to Buy/$178 PT. UNH made a compelling... More

Walgreens Boots Alliance (WBA) on Watch as OptumRx (UNH) and CVS Pharmacy (CVS) Announce Partnership

Walgreens Boots Alliance (NASDAQ: WBA) on watch after OptumRx and CVS Pharmacy (NYSE CVS) announced they are partnering to provide more convenient choices and lower costs for consumers and clients while improving health outcomes. OptumRx is UnitedHealth Group's (NYSE: UNH)... More

Pre-Open Stock Movers 11/29: (CYTR) (VBLT) (THO) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)

Today's Pre-Open Stock Movers

Nivalis Therapeutics (NASDAQ: NVLS) 53.6% LOWER; announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction... More

Jefferies Remains Bullish on UnitedHealth Group (UNH) Following Conference Call

Jefferies reiterated a Buy rating and $168.00 price target on UnitedHealth Group (NYSE: UNH) following the company's 3Q earnings conference call.

Analyst David Windley commented, "CEO Hemsley's supportive comments of 2017 consensus on the 3Q16 earnings call foreshadowed a positive outlook. Considering that... More

Health stocks boost Wall Street; energy a drag

By Caroline Valetkevitch

(Reuters) - U.S. stocks edged higher on Tuesday as an upbeat outlook from UnitedHealth lifted health insurers, though a sharp drop in oil prices weighed on energy shares and limited the advance.

The day's small gains followed a decline in the market on Monday. Analysts said the post-U.S. election rally may be losing momentum, wit the S&P 500 now up roughly 8 percent for the year to date.

Wall Street has risen sharply following Donald Trump's White House win, helped in part by investor expectations that his plans to increase infrastructure spending,... More

After-Hours Stock Movers 09/01: (THO) (TIVO) (VNET) Higher; (NVLS) (FOLD) (SCVL) Lower (more...)

Today's After-Hours Stock Movers

Nivalis Therapeutics (NASDAQ: NVLS) 53.6% LOWER; announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trials primary endpoint, or in sweat chloride reduction at 12... More

UnitedHealth Group (UNH) Issues FY17 Outlook Above the Street Ahead of Investor Day

UnitedHealth Group (NYSE: UNH) will host its annual Investor Conference with analysts and institutional investors in New York City on Tuesday, November 29, 2016, beginning at 8:00 a.m. EST. At the meeting, senior leaders will discuss the Companys performance and outlook, including reviewing business trends and initiatives... More